- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04888988
Test des effets de l'exercice sur la neuropathie périphérique induite par la chimiothérapie (CIPN)
Essai multicentrique randomisé contrôlé de phase II sur l'exercice pour traiter la neuropathie périphérique induite par la chimiothérapie (NPCI)
This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual approach for treating CIPN is treatment with drugs that help reduce symptoms of other types of neuropathy (for example, from diabetes). However, these drugs do not treat all symptoms of CIPN. Exercise may help to reduce CIPN symptoms.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
PRIMARY OBJECTIVE:
I. Assess the preliminary efficacy of exercise versus (vs.) standard care for treating CIPN (via patient-reported CIPN-20 total score).
SECONDARY OBJECTIVES:
I. Assess the preliminary efficacy of exercise vs. standard care on individual symptoms of CIPN (via CIPN Symptom Inventory; i.e., numbness, tingling, burning/shooting pain, and cramping in the hands and feet).
II. Assess the preliminary efficacy of exercise vs. standard care on a clinical test of CIPN symptoms (via the tactile sensitivity in the fingers and toes).
III. Assess the effects of exercise vs. standard care on two possible CIPN mechanisms, namely interoception (via Multidimensional Assessment of Interoceptive Awareness version 2 [MAIA-2] questionnaire).
EXPLORATORY OBJECTIVES:
I. Assess the effects of exercise vs. standard care on other common symptoms related to cancer, chemotherapy, and CIPN, including:
Ia. Daily Diary of symptoms of CIPN. Ib. An array of cancer and treatment symptoms (MD Anderson Symptom Inventory; MDASI).
Ic. Anxiety and depression (hospital anxiety and depression scale; HADS). Id. Pain catastrophizing (pain catastrophizing scale; PCS). Ie. Cognitive impairment (Functional Assessment of Cancer Therapy-Cognitive [FACT-Cog]).
If. Fatigue (brief fatigue inventory; BFI). Ig. Quality of life (Functional Assessment of Cancer Therapy - General [FACT-G]).
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM 1 (EXERCISE): Participants undergo the exercise for cancer patients (EXCAP) intervention consisting of a home-based, self-directed, individually tailored progressive walking and resistance program for up to 6 weeks. Participants also undergo a tactile sensitivity test at baseline and after completion of EXCAP over 15-25 minutes. In addition, participants meet with a certified exercise instructor over 45 minutes at baseline and 2 additional booster meetings over 15-30 minutes during weeks 2 and 3 or weeks 4 and 5.
ARM 2 (CONTROL): Participants receive usual care for 6 weeks. At the end of the study, participants may receive the exercise kit and complete the EXCAP program as in Arm 1. Participants also undergo a tactile sensitivity test at baseline and after completion of EXCAP over 15-25 minutes.
Participants may optionally undergo magnetic resonance imaging (MRI) on study.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
Fresno, California, États-Unis, 93720
- Kaiser Permanente-Fresno
-
Martinez, California, États-Unis, 94553-3156
- Contra Costa Regional Medical Center
-
Roseville, California, États-Unis, 95661
- Kaiser Permanente-Roseville
-
Sacramento, California, États-Unis, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, États-Unis, 95823
- Kaiser Permanente-South Sacramento
-
San Jose, California, États-Unis, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, États-Unis, 94577
- Kaiser Permanente San Leandro
-
San Rafael, California, États-Unis, 94903
- Kaiser San Rafael-Gallinas
-
Santa Clara, California, États-Unis, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
South San Francisco, California, États-Unis, 94080
- Kaiser Permanente-South San Francisco
-
Vallejo, California, États-Unis, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, États-Unis, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Boulder, Colorado, États-Unis, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, États-Unis, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, États-Unis, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Denver, Colorado, États-Unis, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, États-Unis, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, États-Unis, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, États-Unis, 80209
- The Women's Imaging Center
-
Englewood, Colorado, États-Unis, 80113
- Rocky Mountain Cancer Centers - Swedish
-
Englewood, Colorado, États-Unis, 80113
- The Melanoma and Skin Cancer Institute
-
Lakewood, Colorado, États-Unis, 80228
- Rocky Mountain Cancer Centers-Lakewood
-
Littleton, Colorado, États-Unis, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, États-Unis, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont, Colorado, États-Unis, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Thornton, Colorado, États-Unis, 80260
- Rocky Mountain Cancer Centers-Thornton
-
-
Delaware
-
Millville, Delaware, États-Unis, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, États-Unis, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, États-Unis, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, États-Unis, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- MedStar Washington Hospital Center
-
Washington D.C., District of Columbia, États-Unis, 20007
- MedStar Georgetown University Hospital
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, États-Unis, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, États-Unis, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, États-Unis, 96826
- Kapiolani Medical Center for Women and Children
-
‘Aiea, Hawaii, États-Unis, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, États-Unis, 96701
- Pali Momi Medical Center
-
-
Illinois
-
Carterville, Illinois, États-Unis, 62918
- SIH Cancer Institute
-
Centralia, Illinois, États-Unis, 62801
- Centralia Oncology Clinic
-
Danville, Illinois, États-Unis, 61832
- Carle at The Riverfront
-
Decatur, Illinois, États-Unis, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, États-Unis, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, États-Unis, 62401
- Crossroads Cancer Center
-
O'Fallon, Illinois, États-Unis, 62269
- Cancer Care Center of O'Fallon
-
Urbana, Illinois, États-Unis, 61801
- Carle Cancer Center
-
-
Iowa
-
Cedar Rapids, Iowa, États-Unis, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, États-Unis, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, États-Unis, 50314
- Mercy Medical Center - Des Moines
-
-
Maryland
-
Elkton, Maryland, États-Unis, 21921
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, États-Unis, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, États-Unis, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, États-Unis, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, États-Unis, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, États-Unis, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, États-Unis, 48118
- Chelsea Hospital
-
Grand Rapids, Michigan, États-Unis, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Lansing, Michigan, États-Unis, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, États-Unis, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Ypsilanti, Michigan, États-Unis, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Coon Rapids, Minnesota, États-Unis, 55433
- Mercy Hospital
-
Fridley, Minnesota, États-Unis, 55432
- Unity Hospital
-
Minneapolis, Minnesota, États-Unis, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, États-Unis, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, États-Unis, 55101
- Regions Hospital
-
Waconia, Minnesota, États-Unis, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, États-Unis, 56201
- Rice Memorial Hospital
-
-
Missouri
-
Osage Beach, Missouri, États-Unis, 65065
- Lake Regional Hospital
-
St Louis, Missouri, États-Unis, 63131
- Missouri Baptist Medical Center
-
-
North Carolina
-
Gastonia, North Carolina, États-Unis, 28054
- CaroMont Regional Medical Center
-
Lincolnton, North Carolina, États-Unis, 28092
- CaroMont Health - Lincoln Cancer Center
-
Pinehurst, North Carolina, États-Unis, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Rocky Mount, North Carolina, États-Unis, 27804
- Nash UNC HealthCare
-
-
Ohio
-
Belpre, Ohio, États-Unis, 45714
- Strecker Cancer Center-Belpre
-
Lancaster, Ohio, États-Unis, 43130
- Fairfield Medical Center
-
Lima, Ohio, États-Unis, 45801
- Saint Rita's Medical Center
-
Marietta, Ohio, États-Unis, 45750
- Marietta Memorial Hospital
-
Newark, Ohio, États-Unis, 43055
- Licking Memorial Hospital
-
Portsmouth, Ohio, États-Unis, 45662
- Southern Ohio Medical Center
-
Zanesville, Ohio, États-Unis, 43701
- Genesis Healthcare System Cancer Care Center
-
-
South Carolina
-
Boiling Springs, South Carolina, États-Unis, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, États-Unis, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, États-Unis, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, États-Unis, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, États-Unis, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, États-Unis, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, États-Unis, 29672
- Prisma Health Cancer Institute - Seneca
-
-
Virginia
-
Chesapeake, Virginia, États-Unis, 23320
- Chesapeake Regional Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, États-Unis, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, États-Unis, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Sturgeon Bay, Wisconsin, États-Unis, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Have a diagnosis of cancer
- Have received neurotoxic chemotherapy within the past nine months (could still be on chemotherapy or have already completed chemotherapy; i.e., taxane-, platinum-, vinca alkaloid-, epothilone-, or proteasome inhibitor-based chemotherapy
- Report one or more symptoms of CIPN at a level of >= 4 on the CIPN symptom inventory on the Screening Form
- Have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Have at least six months life expectancy
- Be at least 18 years of age
- Be able to read and understand English
- Be able to provide written informed consent
Exclusion Criteria:
- Have physical limitations (e.g., cardiorespiratory, orthopedic, central nervous system) that contraindicate participation in a low to moderate intensity home-based walking and progressive resistance exercise program, according to the participant's physician (e.g., oncologist, primary care) or physician's designee
- Be identified as in the active or maintenance stage of exercise behavior per the Exercise Stages of Change Question on the Screening Form
- Have planned surgery or radiation treatment during the course of the study (hormonal and biologic therapy is allowed)
- Have contraindications for MRI scanning, per the MRI safety screening procedures of the MRI facility to be utilized for this participant
- Are pregnant of have plans to become pregnant during the course of the study. Documentation of pregnancy and use of contraception can be obtained from the medical record.
- Have a current or prior cancer in the central nervous system (spine, brainstem, brain) as this would interfere with assessments of brain functional connectivity.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm 1 (EXCAP, tactile sensitivity test, counseling)
Participants undergo the EXCAP intervention consisting of a home-based, self-directed, individually tailored progressive walking and resistance program for up to 6 weeks. Participants also undergo a tactile sensitivity test at baseline and after completion of EXCAP over 15-25 minutes. In addition, participants meet with a certified exercise instructor over 45 minutes at baseline and 2 additional booster meetings over 15-30 minutes during weeks 2 and 3 or weeks 4 and 5. Participants may optionally undergo MRI on study. |
Undergo MRI
Autres noms:
Ancillary studies Meet with certified exercise instructor Participate in the EXCAP program Undergo tactile sensitivity test
Autres noms:
|
|
Comparateur actif: Arm 2 (usual care, tactile sensitivity test)
Participants receive usual care for 6 weeks. At the end of the study, participants may receive the exercise kit and complete the EXCAP program as in Arm 1. Participants also undergo a tactile sensitivity test at baseline and after completion of EXCAP over 15-25 minutes. Participants may optionally undergo MRI on study. |
Undergo MRI
Autres noms:
Ancillary studies Meet with certified exercise instructor Participate in the EXCAP program Undergo tactile sensitivity test
Autres noms:
Receive standard of care
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Chemotherapy-induced peripheral neuropathy (CIPN) symptom severity
Délai: Week 6 post randomization
|
Will estimate the effects of exercise versus usual care on CIPN using analysis of covariance (ANCOVA). Will be measured by the mean European Organization for Research and Treatment of Cancer-CIPN20. The model will include CIPN-20 at Week 6 as the outcome, treatment group (exercise vs. usual care) as the independent variable of interest and the pre-intervention CIPN-20 score as a covariate. |
Week 6 post randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Effects of exercise on the severity of CIPN symptoms
Délai: Up to 6 weeks post randomization
|
We will estimate the effects of exercise vs. usual care on CIPN symptoms (i.e., hot/burning or sharp/shooting pain in the hands or feet, numbness or tingling in the hands or feet) collected from the daily symptom inventory (0-10 severity) using analysis of covariance (ANCOVA). The model will include the average of daily symptom inventory for each CIPN symptom at post-intervention as the outcome, controlling for the average of daily symptom inventory for each CIPN symptom at pre-intervention. |
Up to 6 weeks post randomization
|
|
Effects of exercise on tactile sensitivity
Délai: Up to 6 weeks post randomization
|
We will estimate the effects of exercise vs. usual care on tactile sensitivity in the fingers and toes, assessed via an established touch test procedure with a set of monofilaments, using analysis of covariance (ANCOVA). The model will include the tactile sensitivity score at post-intervention as the outcome, controlling for the pre-intervention score. |
Up to 6 weeks post randomization
|
|
Effect of exercise on interoception
Délai: Up to 6 weeks post randomization
|
We will estimate the effects of exercise vs. usual care on interoception, measured via the Multidimensional Assessment of Interoceptive Awareness version 2 (MAIA-2), using analysis of covariance (ANCOVA). The model will include the MAIA-2 total score at post-intervention as the outcome, controlling for the pre-intervention MAIA-2 total score. |
Up to 6 weeks post randomization
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Ian R Kleckner, University of Rochester NCORP Research Base
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies hématologiques
- Maladies hémiques et lymphatiques
- Tumeurs hématologiques
- Administration des services de santé
- Qualité des soins de santé, accès et évaluation
- Techniques d'investigation
- Thérapeutique
- Qualité des soins de santé
- Indicateurs de qualité, soins de santé
- Techniques de chimie, analytique
- Analyse du spectre
- Contrôle du comportement
- Immobilisation
- Lignes directrices comme sujet
- Assurance qualité, soins de santé
- Standard de soins
- Spectroscopie de résonance magnétique
- Retenue, physique
- Pratiquez les directives comme sujet
Autres numéros d'identification d'étude
- URCC19075
- UG1CA189961 (Subvention/contrat des NIH des États-Unis)
- URCC19075 (Autre identifiant: University of Rochester NCORP Research Base)
- NCI-2020-11456 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- URCC-19075 (Autre identifiant: CTEP)
- R21CA256154 (Subvention/contrat des NIH des États-Unis)
- URCC-19075 (Autre identifiant: DCP)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .